Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP

The recent classification of pediatric thrombotic microangiopathies (TMA) takes into consideration mechanisms of disease for guidance to targeted therapies. We present our experience with seven patients with antibody mediated atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic...

Full description

Bibliographic Details
Main Authors:	Kata Kelen, Orsolya Horváth, Éva Kis, Bálint Mikes, Péter Sallay, Zoltán Prohászka, Attila József Szabó, György S. Reusz
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	International Journal of Molecular Sciences
Subjects:	thrombotic microangiopathy aHUS TTP immunosuppression eculizumab
Online Access:	https://www.mdpi.com/1422-0067/24/18/14389

Similar Items

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
by: A. Inkeri Lokki, et al.
Published: (2020-04-01)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
by: Mustafa N. Yenerel
Published: (2014-08-01)

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Case Report with <i>MCP</i> Gene Mutation and Successful Eculizumab Treatment
by: Alex Domínguez-Vargas, et al.
Published: (2024-01-01)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
by: Romy N. Bouwmeester, et al.
Published: (2021-01-01)

Thrombotic Microangiopathy with Complement Factor H Gene Mutations Unassociated with Atypical Hemolytic Uremic Syndrome
by: Yesim Oymak, et al.
Published: (2015-07-01)

Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?
by: Andrea Spasiano, et al.
Published: (2023-09-01)

An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry
by: Len Woodward, et al.
Published: (2016-11-01)

Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer
by: Martin Hausberg, et al.
Published: (2019-01-01)

Pregnancy in Complement-Mediated Thrombotic Microangiopathy: Maternal and Neonatal OutcomesPlain Language Summary
by: Natalja Haninger-Vacariu, et al.
Published: (2023-07-01)

Antibody-mediated rejection and aHUS in renal graft recipient
by: Hafez Ibrahim, et al.
Published: (2016-12-01)

Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality
by: Gianluigi Ardissino, et al.
Published: (2021-06-01)

Pediatric Atypical Hemolytic Uremic Syndrome Advances
by: Rupesh Raina, et al.
Published: (2021-12-01)

Favorable course of previously undiagnosed Methylmalonic Aciduria with Homocystinuria (cblC type) presenting with pulmonary hypertension and aHUS in a young child: a case report
by: Luciano De Simone, et al.
Published: (2018-08-01)

A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome
by: Saeed AlZabali, et al.
Published: (2022-11-01)

Hypertensive Emergency with Thrombotic Microangiopathy or TTP? A Case Series and Literature Review
by: Yang Song, et al.
Published: (2024-03-01)

Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD
by: Edwin K. S. Wong, et al.
Published: (2021-01-01)

Compound Haplotype Variants in <i>CFH</i> and <i>CD46</i> Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)—A Series of Cases from a Single Family
by: Agnieszka Furmańczyk-Zawiska, et al.
Published: (2021-04-01)

The utility of platelet activation biomarkers in thrombotic microangiopathies
by: Mohammad Al-Tamimi, et al.
Published: (2022-05-01)

Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report
by: Mihriban İnözü, et al.
Published: (2022-12-01)

Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation
by: Emma Diletta Stea, et al.
Published: (2022-11-01)

An insidious presentation of thrombotic thrombocytopenic purpura: A case report and brief literature review
by: Shafeek Kiblawi, et al.
Published: (2014-01-01)

Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim
by: Muhammad Awidi, et al.
Published: (2021-02-01)

Thrombotic microangiopathy in children: Redefining hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and related disorders
by: Mamta Manglani, et al.
Published: (2024-03-01)

Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
by: Elena Román, et al.
Published: (2017-09-01)

Atypical Hemolytic Uremic Syndrome post Kidney Transplantation: Two Case Reports and Review of the Literature
by: Sami eAlasfar, et al.
Published: (2014-12-01)

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis
by: Sanober Sadiq, et al.
Published: (2023-05-01)

Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
by: Katerina Pavenski
Published: (2021-07-01)

Emergency Plasmapheresis in a case of ThromboticThrombocytopenic Purpura (TTP)
by: Mariaserena Pioli Di Marco, et al.
Published: (2013-12-01)

Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature
by: Matija Matošević, et al.
Published: (2023-02-01)

The Rationale of Complement Blockade of the MCP<sub>ggaac</sub> Haplotype following Atypical Hemolytic Uremic Syndrome of Three Southeastern European Countries with a Literature Review
by: Daniel Turudic, et al.
Published: (2023-08-01)

Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?
by: Stefano Lancellotti, et al.
Published: (2023-04-01)

Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
by: Stefanie W. Benoit, et al.
Published: (2022-02-01)

THROMBOTIC THROMBOCYTOPENIC PURPURA: A CASE REPORT AND REVIEW OF LITERATURE
by: Stankovikj Svetlana
Published: (2020-06-01)

Vascular Occlusion in Kidney Biopsy Is Characteristic of Clinically Manifesting Thrombotic Microangiopathy
by: Marja Kovala, et al.
Published: (2022-05-01)

A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome - Case Report
by: Shirley Pollack, et al.
Published: (2021-06-01)

End-Stage Kidney Disease Resulting from Atypical Hemolytic Uremic Syndrome after Receiving AstraZeneca SARS-CoV-2 Vaccine: A Case Report
by: Mohammed Tawhari, et al.
Published: (2023-03-01)

COVID‐19‐induced thrombotic microangiopathy: A great mimicker of thrombotic thrombocytopenic purpura (TTP)
by: Brian Warnecke, et al.
Published: (2023-01-01)

Ockham’s razor defeated: about two atypical cases of hemolytic uremic syndrome
by: Chloe Schwarz, et al.
Published: (2020-07-01)

Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease
by: Cristina Fernández, et al.
Published: (2015-12-01)

The conundrum of postpartum thrombotic Microangiopathy: case report and considerations for management
by: Katharina Artinger, et al.
Published: (2019-03-01)